论文部分内容阅读
目的:评价奥美沙坦酯对老年高血压患者肌酐清除率的影响。方法:42例老年高血压患者随机接受奥美沙坦酯20 mg或氯沙坦50 mg,qd治疗,总疗程8周。结果:奥美沙坦酯组和氯沙坦组治疗前后肌酐清除率均有不同程度上升,但与治疗前相比无统计学差异,两组间差异无统计学意义(P>0.05)。奥美沙坦酯组和氯沙坦组均未出现不良反应。结论:老年高血压患者应用奥美沙坦酯后肌酐清除率有轻度上升,提升对肾脏有保护作用。
Objective: To evaluate the effect of olmesartan medoxomil on creatinine clearance in elderly hypertensive patients. Methods: Forty-two elderly patients with hypertension were randomized to receive 20 mg olmesartan medoxomil or 50 mg losartan qd for 8 weeks. Results: Both creatinine clearance rate in olmesartan medoxomil group and losartan group increased to some extent before and after treatment, but there was no significant difference between before and after treatment. There was no significant difference between the two groups (P> 0.05). No adverse reactions were observed in the olmesartan medoxomil group and the losartan group. Conclusion: The use of olmesartan medoxomil in elderly hypertensive patients slightly increased creatinine clearance, enhance renal protection.